NT5C and hepatocellular carcinoma: When 3’3’-cyclic AIMP was administered at a later stage after HCC development, tumor regression was observed in the majority of tumors; however, new tumors developed that were not responsive to CDN treatment, supporting the efficacy of this agent in reducing tumor burden but its inability to completely resolve all lesions in multi-focal disease models [106].